NasdaqGS - Nasdaq Real Time Price USD

Recursion Pharmaceuticals, Inc. (RXRX)

Compare
6.50 +0.05 (+0.78%)
At close: September 12 at 4:00 PM EDT
6.55 +0.05 (+0.75%)
After hours: September 12 at 7:49 PM EDT
Loading Chart for RXRX
DELL
  • Previous Close 6.45
  • Open 6.43
  • Bid 6.49 x 1000
  • Ask 6.52 x 1400
  • Day's Range 6.25 - 6.64
  • 52 Week Range 4.97 - 15.74
  • Volume 3,440,906
  • Avg. Volume 5,716,256
  • Market Cap (intraday) 1.835B
  • Beta (5Y Monthly) 0.81
  • PE Ratio (TTM) --
  • EPS (TTM) -1.66
  • Earnings Date Nov 7, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 9.44

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

www.recursion.com

500

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RXRX

View More

Performance Overview: RXRX

Trailing total returns as of 9/12/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RXRX
34.08%
S&P 500
17.32%

1-Year Return

RXRX
21.97%
S&P 500
24.70%

3-Year Return

RXRX
77.02%
S&P 500
25.51%

5-Year Return

RXRX
78.33%
S&P 500
33.69%

Compare To: RXRX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RXRX

View More

Valuation Measures

Annual
As of 9/11/2024
  • Market Cap

    1.82B

  • Enterprise Value

    1.44B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    30.24

  • Price/Book (mrq)

    3.11

  • Enterprise Value/Revenue

    29.53

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -34.35%

  • Return on Equity (ttm)

    -71.18%

  • Revenue (ttm)

    49.63M

  • Net Income Avi to Common (ttm)

    -374.93M

  • Diluted EPS (ttm)

    -1.66

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    474.34M

  • Total Debt/Equity (mrq)

    15.38%

  • Levered Free Cash Flow (ttm)

    -226.71M

Research Analysis: RXRX

View More

Company Insights: RXRX

Research Reports: RXRX

View More

People Also Watch